<(cyclohexyl-1 tetrazolyl-5)-4 butoxy>-7 tetrazolo <1,5-a> quinoleine | 135498-81-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: <(cyclohexyl-1 tetrazolyl-5)-4 butoxy>-7 tetrazolo <1,5-a> quinoleine
• 英文别名: 7-[4-(1-Cyclohexyltetrazol-5-yl)butoxy]tetrazolo[1,5-a]quinoline；7-[4-(1-cyclohexyltetrazol-5-yl)butoxy]tetrazolo[1,5-a]quinoline
• CAS: 135498-81-6
• 化学式: C₂₀H₂₄N₈O
• 分子量: 392.464
• InChiKey: FDWIHZVPQZFDGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  95.9
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  6-[4-(1-环己基-1H-四唑-5-基)丁氧基]-2(1h)-喹啉酮 在 一水合肼 、 溶剂黄146 、 sodium nitrite 、 三氯氧磷 作用下， 反应 26.0h， 生成 <(cyclohexyl-1 tetrazolyl-5)-4 butoxy>-7 tetrazolo <1,5-a> quinoleine
  参考文献：
  名称：

  Dérivés de triazolo[4,3-a]quinoléines et de tétrazolo[1,5-a]quinoléines synthèse, évaluation pharmacologique en tant qu'agents antiagrégants plaquettaires agissant par inhibition de phosphodiestérases

  摘要：

  The lactame-triazole or lactame-tetrazole isostery applied to the quinolinone lactames of compound Y-590 or cilostazole lead to compounds which show similar potencies on platelet specific phosphodiesterase inhibition, platelet aggregation inhibition and antithrombotic effects. On the other hand a supplementary isostery of the same type applied to the pyridazinone carbonyl group of compound Y-590 resulted in a dramatic loss of activity illustrating the importance of the pyridazinone moiety for the observed effects. However, this lactame carbonyl group can be replaced by an amidine or a thioamide group with retention of the activities.

  DOI：

  10.1016/0223-5234(91)90028-l

文献信息

• Dérivés de triazolo[4,3-a]quinoléines et de tétrazolo[1,5-a]quinoléines synthèse, évaluation pharmacologique en tant qu'agents antiagrégants plaquettaires agissant par inhibition de phosphodiestérases
  作者：P Desos、G Schlewer、C Lugnier、A Beretz、JP Maffrand、A Bernat、CG Wermuth

  DOI：10.1016/0223-5234(91)90028-l

  日期：1991.3

  The lactame-triazole or lactame-tetrazole isostery applied to the quinolinone lactames of compound Y-590 or cilostazole lead to compounds which show similar potencies on platelet specific phosphodiesterase inhibition, platelet aggregation inhibition and antithrombotic effects. On the other hand a supplementary isostery of the same type applied to the pyridazinone carbonyl group of compound Y-590 resulted in a dramatic loss of activity illustrating the importance of the pyridazinone moiety for the observed effects. However, this lactame carbonyl group can be replaced by an amidine or a thioamide group with retention of the activities.